Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Chronic Urticaria, Idiopathic
Interventions: Omalizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: PF-08049820, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: S-777469 400 mg, S-777469 800 mg, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more

Conditions: Atopic Dermatitis
Interventions: Colloidal Oatmeal, Topical Cream; Drug · Device
Lead sponsor: Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: St. Petersburg, Florida • Miamiville, Ohio

Conditions: Atopic Dermatitis
Interventions: Sodium hypochlorite (bleach) baths, Mupirocin ointment, Water, Petrolatum Ointment; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Months to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more

Conditions: Asthma, Perennial Allergic Rhinitis
Interventions: Mouse Allergenic Extract; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Atopic Dermatitis
Interventions: ATI-502; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Encinitas, California • San Diego, California • Fridley, Minnesota + 3 more

Conditions: Rheumatoid Arthritis, Insulin Resistance
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more

Conditions: Urticaria, Angioedema, Hives, Swelling
Interventions: High Dose Vitamin D3, Low Dose Vitamin D3; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib phosphate cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Atopic Dermatitis
Interventions: SUN13834, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 28
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 25 more

Conditions: Atopic Dermatitis
Interventions: Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 35
States / cities: Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 0
States / cities: Not listed

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab Injection, Xolair Prefilled Syringe; Drug
Lead sponsor: Kashiv BioSciences, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more

Conditions: Atopic Dermatitis
Interventions: GIA632, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fremont, California • Rockville, Maryland • Hoboken, New Jersey

Conditions: Cannabis Use, Sleep, Circadian Rhythm
Interventions: Cannabis Discontinuation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 25 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: FMX114, Vehicle; Drug · Other
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Atopic Dermatitis
Interventions: MEDI9929, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: North Miami Beach, Florida • Tampa, Florida • Arlington Hts, Illinois + 5 more

Conditions: Melanoma (Skin)
Interventions: reverse transcriptase-polymerase chain reaction, sentinel lymph node biopsy; Genetic · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab vial injection, Rocatinlimab prefilled syringe; Drug · Combination Product
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Search by objective public record fields.

Molecular Endotypes of Chronic Idiopathic Urticaria

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Subcutaneous Immunotherapy for Mouse in Adults

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Quality of Life Study in Adults With Facial Eczema

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Cannabis Effects on Sleep, Circadian Rhythms, and Light Sensitivity in Young Adults

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants